

Company registration number 573618 (Ireland)

PROTEIN ZONE LIMITED
ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

PROTEIN ZONE LIMITED

CONTENTS

| | Page |
|---------------------------------------|-------------|
| Director's responsibilities statement | 1 |
| Balance sheet | 2 |
| Statement of changes in equity | 3 |
| Notes to the financial statements | 4 - 7 |

PROTEIN ZONE LIMITED

DIRECTOR'S RESPONSIBILITIES STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (Generally Accepted Accounting Practice in Ireland) issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for that financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board



Radoslaw Dziubak
Director

29 January 2026

PROTEIN ZONE LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2025

| | Notes | 2025 € | € | 2024 € | € |
|---|-------|---------------|-----------------|---------------|-----------------|
| Current assets | | | | | |
| Stocks | 4 | 66,300 | | 60,000 | |
| Debtors | | 541 | | - | |
| Cash at bank and in hand | | 2,116 | | 3,226 | |
| | | <u>68,957</u> | | <u>63,226</u> | |
| Creditors: amounts falling due within one year | 5 | (93,861) | | (95,799) | |
| Net current liabilities | | | <u>(24,904)</u> | | <u>(32,573)</u> |
| Capital and reserves | | | | | |
| Called up share capital presented as equity | 6 | | 100 | | 100 |
| Profit and loss reserves | 7 | | (25,004) | | (32,673) |
| Total equity | | | <u>(24,904)</u> | | <u>(32,573)</u> |

I, as director of Protein Zone Limited, state that:

(a) the company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014;

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied;

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2); and

(d) the director acknowledges the obligations of the company, under the Companies Act 2014, to:


(i) keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year; and

(ii) to otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.

(e) I have relied on the specified exemption contained in section 352 Companies Act 2014 on the grounds that the company is entitled to the benefit of that exemption as a small company and confirm that the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved and signed by the director and authorised for issue on 29 January 2026



Radoslaw Dziubak
Director

PROTEIN ZONE LIMITED

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2025

| | Share capital | Profit and loss reserves | Total |
|--|------------------|--------------------------------|-----------------|
| | € | € | € |
| Balance at 1 January 2024 | 100 | (41,713) | (41,613) |
| Year ended 31 December 2024: | | | |
| Profit and total comprehensive income for the year | - | 9,040 | 9,040 |
| | <hr/> | <hr/> | <hr/> |
| Balance at 31 December 2024 | 100 | (32,673) | (32,573) |
| Year ended 31 December 2025: | | | |
| Profit and total comprehensive income for the year | - | 7,669 | 7,669 |
| | <hr/> | <hr/> | <hr/> |
| Balance at 31 December 2025 | <u>100</u> | <u>(25,004)</u> | <u>(24,904)</u> |

PROTEIN ZONE LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

Company information

Protein Zone Limited is a limited company domiciled and incorporated in Ireland. The registered office is 20 Abbey Street Upper, Dublin 1, Ireland and its company registration number is 573618.

1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.4 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

PROTEIN ZONE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies (Continued)

1.5 Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

PROTEIN ZONE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies (Continued)

1.8 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

| | 2025 Number | 2024 Number |
|-------|----------------|----------------|
| Total | 3 | 3 |

3 Director's remuneration

| | 2025 € | 2024 € |
|--------------------------------------|-----------|-----------|
| Remuneration for qualifying services | 31,501 | 29,500 |

4 Stocks

| | 2025 € | 2024 € |
|-------------------------------------|-----------|-----------|
| Finished goods and goods for resale | 66,300 | 60,000 |

PROTEIN ZONE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

5 Creditors: amounts falling due within one year

| | 2025 € | 2024 € |
|--|---------------|---------------|
| Trade creditors | 16,161 | 11,307 |
| Other creditors including tax and social insurance | 70,104 | 77,305 |
| Accruals | 7,596 | 7,187 |
| | <u>93,861</u> | <u>95,799</u> |

6 Called up share capital

| | 2025 | 2024 | 2025 | 2024 |
|------------------------------|------------|------------|------------|------------|
| Issued and fully paid | | | | |
| Ordinary Shares of €1 each | 100 | 100 | 100 | 100 |
| | <u>100</u> | <u>100</u> | <u>100</u> | <u>100</u> |

7 Profit and loss reserves

| | 2025 € | 2024 € |
|------------------------------|-----------------|-----------------|
| At the beginning of the year | (32,673) | (41,713) |
| Profit for the year | 7,669 | 9,040 |
| | <u>(25,004)</u> | <u>(32,673)</u> |

8 Capital commitments

There were no material capital commitments at the year ended 31 December 2025.

9 Contingent liabilities

There were no material contingent liabilities at the year ended 31 December 2025.

10 Directors' transactions

| Description | % Rate | Opening balance € | Amounts advanced € | Amounts repaid € | Closing balance € |
|--------------------|-----------|-------------------------|--------------------------|------------------------|-------------------------|
| Radoslaw Dziubak - | - | (72,677) | 40,487 | (32,693) | (64,883) |
| | | <u>(72,677)</u> | <u>40,487</u> | <u>(32,693)</u> | <u>(64,883)</u> |

11 Approval of financial statements

The director approved the financial statements on 29 January 2026.